Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

673
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
673
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

642
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
642
Two-Compartment Open Model: IV Bolus Administration01:18

Two-Compartment Open Model: IV Bolus Administration

1.1K
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
1.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

674
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
674
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

822
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
822

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring How Palliative Care is Delivered: Using Provider Sequences as a New Quality Signal.

Journal of pain and symptom management·2026
Same author

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Hearing loss and incident dementia over 8 years in Black and White older adults: the Atherosclerosis Risk in Communities Neurocognitive Study.

Frontiers in epidemiology·2026
Same author

Quantifying Direct and Indirect Effects through Joint Modeling of Terminal Events and Gap Times between Recurrent Events.

Journal of data science : JDS·2026
Same author

MiniMed<sup><b>™</b></sup> 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvantage.

Diabetes technology & therapeutics·2026
Same author

Effectiveness and safety of trastuzumab-anns compared to reference trastuzumab among patients with HER2-positive breast cancer: A non-inferiority study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.3K

MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses.

Fang Niu1, Margaret Liu1, Caroline Yovanovich1

  • 1Medtronic Diabetes, Northridge, CA.

Diabetes Care
|January 7, 2026
PubMed
Summary
This summary is machine-generated.

The MiniMed 780G system effectively manages glucose levels even when users miss boluses. Using recommended optimal settings (ROS) further improves glycemic control and goal achievement for diabetes management.

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

7.6K
A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

12.4K

Related Experiment Videos

Last Updated: Jan 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.3K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

7.6K
A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

12.4K

Area of Science:

  • Endocrinology
  • Biomedical Engineering
  • Diabetes Technology

Background:

  • The MiniMed 780G (MM780G) is an automated insulin delivery system.
  • Real-world data on its performance without user-initiated boluses is valuable for understanding its efficacy.
  • Assessing the impact of recommended optimal settings (ROS) is crucial for maximizing system benefits.

Purpose of the Study:

  • To evaluate glycemic metrics and insulin delivery using the MM780G system on days users did not administer boluses.
  • To compare outcomes between users employing ROS and those not using ROS.
  • To analyze subgroup differences based on age and diabetes type.

Main Methods:

  • Analysis of global CareLink personal data from 369,467 MM780G users.
  • Identification of 54,553 users with at least 10 days without user-initiated boluses.
  • Evaluation of time in range (TIR), time below range (TBR), time above range, glucose management indicator (GMI), and total insulin delivered, comparing ROS vs. non-ROS users, and by age and diabetes type.

Main Results:

  • On days without boluses, ROS users had a mean sensor glucose of 149.2 mg/dL and 76.3% TIR, versus 159.7 mg/dL and 69.3% TIR for non-ROS users.
  • ROS use was associated with a higher percentage of users achieving consensus TIR, TBR, and GMI goals.
  • Specific subgroup analyses by age and diabetes type were conducted.

Conclusions:

  • The MM780G system demonstrates effective glycemic control even when boluses are missed.
  • Utilizing recommended optimal settings (ROS) leads to a greater proportion of users achieving glycemic targets in real-world settings.
  • These findings support the system's utility for diabetes management with reduced user burden.